Zeidler Lab
The Zeidler lab identifies new tractable target molecules specifically exposed on the surface of tumors and generates and characterizes corresponding first-in-class monoclonal antibodies for future clinical applications. The focus is on actually intracellular molecules that – for unknown reasons – are translocated to the plasma membrane of cancer cells rendering them accessible for targeted therapies.
Reinhard Zeidlers research has been featured in the Helmholtz Munich newsroom
The Zeidler lab identifies new tractable target molecules specifically exposed on the surface of tumors and generates and characterizes corresponding first-in-class monoclonal antibodies for future clinical applications. The focus is on actually intracellular molecules that – for unknown reasons – are translocated to the plasma membrane of cancer cells rendering them accessible for targeted therapies.
Reinhard Zeidlers research has been featured in the Helmholtz Munich newsroom
About us
Tumor-specific monoclonal antibodies
Antibody-based therapy of cancer is one of the most important success stories of personalized medicine. Although the concept that antibodies could serve as 'magic bullets' in the treatment and detection of cancer has a long history, the number of available antibodies is still too small. A key challenge for the development of new therapeutic antibodies for the clinic is the identification of suitable and accessible target molecules on the surface of cancer cells. We pursue a proprietary approach for the generation and evaluation of novel antibodies with a potential for cancer treatment and detection.
Development of a new experimental therapy for Glioblastoma
Glioblastoma multiforme (GBM) is the most common and most aggressive type of brain cancer with a dismal prognosis. As a first translational project, we develop a new experimental immunotherapy for the treatment of glioblastoma. This approach is based on our antibody 6A10 that binds to an enzyme present on the surface of glioblastoma cells but not of normal brain. Equipped with a radioactive payload, the antibody will be injected into the hole that remains after surgical removal of the tumor. From there, the antibody will migrate into the surrounding brain tissue. If it encounters a residual cancer cell, it will bind to this cell and – hopefully – destroy it. Resident tumor cells that remained in the brain after surgery are the origin of recurrent disease, and our approach aims at significantly prolonging recurrence-free survival.
Spin-off company 'Eximmium'
We are actively pursuing the commercialization of our proprietary therapeutic antibody candidates. Eximmium will concentrate on the generation and pre-clinical validation of proprietary first-in-class antibodies. Currently, we are talking with various potential investors.
Group members
Publications
Read more